Stock Events

Stock Events

Search...

LigaChem Biosciences

₩80,900

2

+₩0+0% Today

Statistics

Day High

83,300

Day Low

79,300

52W High

87,200

52W Low

32,400

Volume

505,062

Avg. Volume

710,595

Mkt Cap

2.96T

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

13MayExpected

Q2 2022

Q3 2022

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

-322

-259.58

-197.16

-134.74

Expected EPS

N/A

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 141080.KQ. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Astellas Pharma

Astellas Pharma US, a subsidiary of Astellas Pharma Inc., competes in the therapeutic areas including oncology, similar to LegoChem Biosciences' market.

I-Mab is a biopharma company focused on developing biologics in the field of immuno-oncology and autoimmune diseases, competing in the same biotechnological advancements as LegoChem Biosciences.

BeiGene, Ltd. operates in the global biopharmaceutical market, focusing on innovative molecularly targeted and immuno-oncology drug candidates, similar to LegoChem Biosciences.

Zai Lab Limited

Zai Lab Limited, a biopharmaceutical company, focuses on bringing transformative medicines for cancer, which competes with LegoChem Biosciences' cancer therapy developments.

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma, and allergic diseases, competing in similar fields as LegoChem Biosciences.

SELLAS Life Sciences

SELLAS Life Sciences Group, Inc. focuses on novel cancer immunotherapies, directly competing with LegoChem Biosciences in the innovative cancer treatment sector.

Adaptimmune Therapeutics

Adaptimmune Therapeutics plc specializes in T-cell therapy to treat cancer, competing in the advanced therapy medicinal products sector like LegoChem Biosciences.

About

LigaChem Biosciences Inc. a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, and oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It offers its products in the forms of tablets and capsules. The Company also sells medical device and supplies. It has a research collaboration and license agreement with AMGEN for the development and commercialization of ADCs. LigaChem Biosciences Inc. was founded in 2006 and is headquartered in Daejeon, South Korea.

Show more...

CEO

Mr. Yong Zu Kim

Country

KR

ISIN

KR7141080002

Listings